Steven D. Rubin - 24 Jan 2025 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact for Steven D. Rubin
Issuer symbol
N/A
Transactions as of
24 Jan 2025
Net transactions value
$0
Form type
4
Filing time
28 Jan 2025, 17:36:23 UTC
Previous filing
05 Nov 2024
Next filing
21 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELOX Common Stock Options Exercise $0 +3,750 +31% $0.000000 15,750 24 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Restricted Stock Units Options Exercise $0 -3,750 -50% $0.000000 3,750 24 Jan 2025 Common Stock 3,750 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.